Physician profile
Tae Jung
NPI 1831153006
$1,584.53
in general payments reported to CMS, 2019-2025
21 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $138 · 2021: $12.50 · 2022: $79.43 · 2023: $96.74 · 2024: $44.42 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $278.51 | 2019-2020 | |
| Novo Nordisk INC | $226.59 | 2019-2022 | |
| Amgen INC. | $222.25 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $186.77 | 2019-2025 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $96.47 | 2019-2020 | |
| Pfizer INC. | $95.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $73.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $72.38 | 2019 | |
| Abbvie INC. | $47.58 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $47.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.27 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.51 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $27.85 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $20.56 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.58 | 2019 | |
| Merck Sharp & Dohme LLC | $14.04 | 2020 | |
| Biogen, INC. | $13.34 | 2023 | Spinraza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.27 | 2019 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tae Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.